Sökning: onr:"swepub:oai:DiVA.org:uu-494356" >
Macrophage Activati...
Macrophage Activation Marker Neopterin : A Candidate Biomarker for Treatment Response and Relapse in Visceral Leishmaniasis.
-
Kip, Anke E (författare)
-
Wasunna, Monique (författare)
-
Alves, Fabiana (författare)
-
visa fler...
-
Schellens, Jan H M (författare)
-
Beijnen, Jos H (författare)
-
Musa, Ahmed M (författare)
-
Khalil, Eltahir A G (författare)
-
- Dorlo, Thomas P C (författare)
- Netherlands Cancer Institute
-
visa färre...
-
(creator_code:org_t)
- 2018-06-01
- 2018
- Engelska.
-
Ingår i: Frontiers in Cellular and Infection Microbiology. - : Frontiers Media SA. - 2235-2988. ; 8, s. 181-
- Relaterad länk:
-
https://www.frontier...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- The Leishmania parasite resides and replicates within host macrophages during visceral leishmaniasis (VL). This study aimed to evaluate neopterin, a marker of macrophage activation, as possible pharmacodynamic biomarker to monitor VL treatment response and to predict long-term clinical relapse of VL. Following informed consent, 497 plasma samples were collected from East-African VL patients receiving a 28-day miltefosine monotherapy (48 patients) or 11-day combination therapy of miltefosine and liposomal amphotericin B (L-AMB, 48 patients). Neopterin was quantified with ELISA. Values are reported as median (inter-quartile range). Baseline neopterin concentrations were elevated in all VL patients at 98.8 (63.9-135) nmol/L compared to reported levels for healthy controls (<10 nmol/L). During the first treatment week, concentrations remained stable in monotherapy patients (p = 0.807), but decreased two-fold compared to baseline in the combination therapy patients (p < 0.01). In the combination therapy arm, neopterin concentrations increased significantly 1 day after L-AMB infusion compared to baseline for cured patients [137 (98.5-197) nmol/L, p < 0.01], but not for relapsing patients [84.4 (68.9-106) nmol/L, p = 0.96]. The neopterin parameter with the highest predictive power for VL relapse was a higher than 8% neopterin concentration increase between end of treatment and day 60 follow-up (ROC AUC 0.84), with a 93% sensitivity and 65% specificity. In conclusion, the identified neopterin parameter could be a potentially useful surrogate endpoint to identify patients in clinical trials at risk of relapse earlier during follow-up, possibly in a panel of biomarkers to increase its specificity.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Mikrobiologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Microbiology in the medical area (hsv//eng)
Nyckelord
- biomarker
- kala-azar
- liposomal amphotericin B
- macrophage activation
- miltefosine
- neopterin
- pharmacodynamics
- visceral leishmaniasis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas